Goal achievement of HbA1c and LDL-cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCT.
Harpreet S BajajRuth E BrownDishay JiandaniKarri VennHani Al-AsaadHasnain KhandwalaOren SteenSuzan Abdel-SalamRonnie AronsonPublished in: Diabetes, obesity & metabolism (2020)
Among subjects with T2D, the initiation of colesevelam or ezetimibe led to similar achievement of primary composite outcome (LDL-c and HbA1c within target), with ezetimibe recording a greater LDL-c reduction and better tolerability than colesevelam.